| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 4.39 Billion |
| Market Size (2030) | USD 11.84 Billion |
| CAGR (2025 - 2030) | 21.95 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Single-Cell Multiomics Market Analysis
The Single-Cell Multiomics Market size is estimated at USD 4.39 billion in 2025, and is expected to reach USD 11.84 billion by 2030, at a CAGR of 21.95% during the forecast period (2025-2030).
Advancements in single-cell analysis technologies and products are contributing to the expansion of single-cell multiomics. The increasing use of single-cell RNA sequencing in large-scale genomics studies further drives this growth. The increasing adoption of personalized medicine for screening and diagnosing genetic disorders also promotes the growth of the single-cell multiomics market.
Various gene therapies, diagnostics, and medicines in single-cell multiomics have been introduced in recent years due to the increasing prevalence of life-threatening conditions like cancer and rare diseases. In precision medicine, multiomic strategies facilitate the integration of diverse omics data to improve the diagnosis and treatment of cancer and other chronic diseases. For instance, a report published by the National Cancer Institute in May 2024 projected that approximately 2.0 million individuals in the United States will receive a cancer diagnosis in 2024, and breast cancer is anticipated to affect 310,720 women in the country. Prostate cancer is expected to be the primary diagnosis among men and second overall, with an estimated 299,010 cases anticipated. Lung and bronchus cancer is expected to be the third most frequently diagnosed cancer, with approximately 234,580 new cases in 2024.
Similarly, the statistics from the Australia Institute of Health and Welfare published in August 2023 stated that approximately 162,000 new cancer incidences were observed in Australia in 2022, which rose to 165,000 in 2023. In addition, as per the same source, prostate, colorectal, and lung cancers were the most frequently diagnosed cancers in men. The rising incidence of cancer cases is expected to increase the demand for precision medicine for effective patient treatment, which may necessitate the use of single-cell multiomics that provide transformative insights into the clinical and molecular features of cancers. Thus, given the aforementioned factors, the market is expected to record high growth over the forecast period.
Such factors also promote collaboration between biologists, physicians, technology developers, data scientists, patient groups, and government bodies to achieve the goals of precision medicine. For instance, in November 2022, NanoString Technologies Inc. and Abcam strengthened their ongoing collaboration through a new agreement to co-market Abcam's antibodies. This partnership was aimed at enhancing the capabilities of NanoString’s high-plexity spatial and multi-omic solutions.
In October 2022, a strategic research collaboration between Illumina and AstraZeneca was announced to enhance drug target discovery through the integration of AI-based genome interpretation and genomic analysis techniques. This partnership was expected to enable AstraZeneca's Center for Genomics Research to utilize a combined AI-based framework for analyzing extensive multiomics data sets within its digital biobank. Collaborations and new program initiatives are anticipated to drive market expansion throughout the forecast period.
However, the elevated costs of single-cell analysis products and a shortage of skilled professionals are projected to impede market growth.
Single-Cell Multiomics Market Trends
The Oncology Segment is Expected to Witness High Growth Over the Forecast Period
Single-cell multiomics has brought transformative insights into immuno-oncology, demonstrating success in describing novel immune subsets and defining important regulators of antitumor immunity. Single-cell multiomics applications are increasingly focusing on enhancing the treatment of oncological conditions and are expected to hold a significant market share. Moreover, the growing incidence of cancer and the expanding pipeline of drug candidates undergoing clinical trials for these diseases are also propelling the segment’s growth.
As per clinicaltrials.gov, as of July 2024, there were more than 27,000 active, ongoing clinical trials in the area of oncology, compared to 23,500 in November 2022. The extensive global focus on cancer research highlights the critical role of cellular, metabolic, and genetic analysis in understanding various cancers. This deeper understanding facilitates the development of effective diagnostics, therapeutics, and treatment strategies. Consequently, the adoption of single-cell multiomics in research applications is anticipated to experience substantial growth.
The rising demand for novel treatment therapies for single-cell multiomics is propelling the growth of the segment. For instance, according to a report published by the Nature Communications Journal in December 2023, oncology single-cell multiomics provides crucial insights into intra-cell-line heterogeneity, enabling more precise cancer models for drug testing and mechanistic investigations. The comprehensive dataset and novel methodologies offered by the study drive innovation and accuracy in cancer research, fostering the development of targeted therapies and high-throughput screening technologies. Thus, the segment is expected to record growth in the near future due to the above-mentioned factors.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Hold a Significant Market Share in the Forecast Period
Enhanced healthcare infrastructure and substantial investment in research and development are anticipated to drive the expansion of the single-cell multiomics market in North America. Significant progress in precision medicine has been made for various diseases, including neurological disorders and cancers such as colorectal and breast cancer.
The rising cases of cancer are propelling the growth of the market by increasing the demand for advanced, precise technologies that can offer deeper insights into cancer heterogeneity and support the development of targeted therapies. For instance, the Canadian Cancer Society's September 2023 report indicated that cancer constituted a significant healthcare burden in Canada, with its incidence rates on the rise. In 2023, 124,200 men and 114,900 women were diagnosed with cancer.
As per the same source, lung and bronchus cancer, breast cancer, prostate cancer, and colorectal cancer were the top four cancers, accounting for 46% of cancer diagnoses in the country in 2023.
According to National Information Center (NIC) data updated in March 2022, the Consolidated Appropriations Act 2022 allocated USD 6.9 billion to NIC, a USD 353 million net increase over the previous year. In the FY 2022 allocation, USD 194 million was designated for the Cancer Moonshot and USD 50 million for the Childhood Cancer Data Initiative. These substantial investments in advancing precision medicine are expected to significantly drive demand for single-cell multiomics techniques during the forecast period. Additionally, the presence of leading market players and the introduction of new products are anticipated to boost the market's growth.
Moreover, in November 2022, Freenome disclosed the participation of 50 hospitals and community oncology practices across the United States as clinical partners in its Vallania Study. The study aims to detect multiple cancers by leveraging Freenome's multiomics platform, which combines tumor and non-tumor signals with machine learning to identify early-stage cancers through a simple blood test. These strategic partnerships are anticipated to drive the demand for single-cell multiomics platforms, thereby contributing to regional market growth.
Hence, due to the factors mentioned above, the market is expected to grow at a good pace over the forecast period.
Get Analysis on Important Geographic Markets
Download PDF
Single-Cell Multiomics Industry Overview
The single-cell multiomics market is moderately consolidated. The major players in the market include BGI Genomics Co. Ltd, Bio-Rad Laboratories Inc., Danaher Corporation (Cytiva Life Sciences), Vizgen Inc., Illumina Inc., Mission Bio Inc., NanoString Technologies Inc., Qiagen NV, Takara Holdings Inc. (Takara Bio Group), and Standard BioTools Inc.
Single-Cell Multiomics Market Leaders
-
BGI Genomics Co. Ltd.
-
Bio-Rad Laboratories, Inc.
-
Danaher Corporation (Cytiva Life sciences)
-
Illumina Inc
-
Standard BioTools Inc
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Single-Cell Multiomics Market News
- June 2024: Mission Bio launched its Tapestri Single-cell Multiple Myeloma Multiomics Solution. This solution is designed to transform the way multiple myeloma (MM) research and therapeutic development is done. The new product suite provides comprehensive clonal and subclonal insights into disease evolution and biology at the single-cell level beyond what existing bulk methodologies can offer.
- May 2024: Parse Biosciences launched its Evercode BCR and expanded its existing Evercode TCR product line. The new BCR solution and updates to the existing TCR product line expand Parse’s single-cell portfolio.
Single-Cell Multiomics Industry Segmentation
Single-cell multiomics technologies measure various molecules from the same individual cell, providing deeper biological insights than analyzing separate molecular layers from different cells. Additionally, these technologies uncover cellular heterogeneity across multiple molecular layers within a cell population, highlighting how variations are interconnected or distinct between the captured omic layers.
The single-cell multiomics market is segmented by type, application, end user, and geography. The type segment is further segmented into single-cell genomics, single-cell proteomics, single-cell transcriptomics, and single-cell metabolomics. By application, the market is segmented into cell biology, neurology, oncology, and other applications. The end-user segment is divided into academic & research institutes, biotechnology & pharmaceutical companies, and other end users. The geography segment is further divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (USD) for all the above segments.
| By Type | Single Cell Genomics | ||
| Single Cell Proteomics | |||
| Single Cell Transcriptomics | |||
| Single Cell Metabolomics | |||
| By Application | Cell Biology | ||
| Neurology | |||
| Oncology | |||
| Other Application (Immunology, Stem Cell Reserch) | |||
| By End User | Academic & Research Institutes | ||
| Biotechnology & Pharmaceutical Companies | |||
| Other End-Users | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Single-Cell Multiomics Market Research FAQs
How big is the Single-Cell Multiomics Market?
The Single-Cell Multiomics Market size is expected to reach USD 4.39 billion in 2025 and grow at a CAGR of 21.95% to reach USD 11.84 billion by 2030.
What is the current Single-Cell Multiomics Market size?
In 2025, the Single-Cell Multiomics Market size is expected to reach USD 4.39 billion.
Who are the key players in Single-Cell Multiomics Market?
BGI Genomics Co. Ltd., Bio-Rad Laboratories, Inc., Danaher Corporation (Cytiva Life sciences), Illumina Inc and Standard BioTools Inc are the major companies operating in the Single-Cell Multiomics Market.
Which is the fastest growing region in Single-Cell Multiomics Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Single-Cell Multiomics Market?
In 2025, the North America accounts for the largest market share in Single-Cell Multiomics Market.
What years does this Single-Cell Multiomics Market cover, and what was the market size in 2024?
In 2024, the Single-Cell Multiomics Market size was estimated at USD 3.43 billion. The report covers the Single-Cell Multiomics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Single-Cell Multiomics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Single-Cell Multiomics Industry Report
Statistics for the 2025 Single-Cell Multiomics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Single-Cell Multiomics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
